SCHEMBL10072110

SCHEMBL10072110

Cc1ccc(-c2cnn3c(-c4ccc(F)cc4)cc(Cl)nc23)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT1 P42224 2/20 0.64
RAB9A P51151 13/20 0.54
NPC1 O15118 11/20 0.54
MAPT P10636 10/20 0.54
MEN1 O00255 9/20 0.54
KMT2A Q03164 9/20 0.54
SMN1; SMN2 Q16637 6/20 0.54
KDM4E B2RXH2 5/20 0.54
POLB P06746 1/20 0.52
L3MBTL1 Q9Y468 3/20 0.51
ALDH1A1 P00352 5/20 0.48
NFKB1 P19838 2/20 0.48
NFKB2 Q00653 2/20 0.48
RELA Q04206 2/20 0.48
CASP3 P42574 1/20 0.46
BLM P54132 1/20 0.46
NCOA1 Q15788 1/20 0.46
SENP8 Q96LD8 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
SENP6 Q9GZR1 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15121534 0.81 RAB9A (0.49) STAT1RAB9ANPC1MAPTMEN1
SCHEMBL257382 0.77 TP53 (0.53) NPC1MAPTMEN1KMT2APOLB
Pyrimidine SCHEMBL15020788 0.74 STAT1 (0.46) STAT1RAB9ANPC1MAPTMEN1
SCHEMBL257503 0.73 ALDH1A1 (0.50) MAPTKMT2ASMN1; SMN2KDM4EPOLB
SCHEMBL31624150 0.73 POLB (0.53) STAT1RAB9ANPC1MAPTMEN1
SCHEMBL257419 0.73 STAT1 (0.49) STAT1RAB9ANPC1MAPTMEN1
SCHEMBL15021303 0.73 STAT1 (0.49) STAT1RAB9ANPC1MAPTMEN1
SCHEMBL257314 0.71 TP53 (0.41) STAT1RAB9ANPC1MAPTMEN1
SCHEMBL257430 0.71 PLAT (0.61) STAT1
SCHEMBL22520981 0.70 RAB9A (0.71) STAT1RAB9ANPC1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
EP-2617723-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR Amorepacific Corporation (KR) 2013-07-24 EP disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
WO-2012030170-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR (주)아모레퍼시픽 (KR) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR CNR1, CNR2, GPR18 STAT1 2921/4885RAB9A 542/4885NPC1 114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.